一种基于荧光激发态分子内质子转移的苯并咪唑平台，用于ONOO 和的比率双光子成像。

A fluorescent ESIPT-based benzimidazole platform for the ratiometric two-photon imaging of ONOO and .

作者信息

Odyniec Maria L, Park Sang-Jun, Gardiner Jordan E, Webb Emily C, Sedgwick Adam C, Yoon Juyoung, Bull Steven D, Kim Hwan Myung, James Tony D

机构信息

Department of Chemistry , University of Bath , BA2 7AY , UK . Email:

Department of Chemistry , Ajou University , 16499 , Suwon , Korea . Email:

出版信息

Chem Sci. 2020 Jun 16;11(28):7329-7334. doi: 10.1039/d0sc02347g. eCollection 2020 Jul 28.

In this work, we have developed an ESIPT-based benzimidazole platform ( and ) for the two-photon cell imaging of ONOO and a potential ONOO-activated theranostic scaffold (). Each benzimidazole platform, , were shown to rapidly detect ONOO at micromolar concentrations (LoD = 0.28 μM, 6.53 μM and 0.81 μM respectively). The potential theranostic was shown to release the parent fluorophore and drug indomethacin in the presence of ONOO but unfortunately did not perform well due to low solubility. Despite this, the parent scaffold demonstrated its effectiveness as a two-photon imaging tool for the ratiometric detection of endogenous ONOO in RAW264.7 macrophages and rat hippocampus tissue. These results demonstrate the utility of this ESIPT benzimidazole-based platform for theranostic development and bioimaging applications.

在这项工作中，我们开发了一种基于激发态分子内质子转移（ESIPT）的苯并咪唑平台（以及）用于ONOO的双光子细胞成像和一种潜在的ONOO激活的诊疗支架（）。每个苯并咪唑平台，分别显示出能在微摩尔浓度下快速检测ONOO（检测限分别为0.28 μM、6.53 μM和0.81 μM）。潜在的诊疗剂在ONOO存在的情况下显示出能释放母体荧光团和药物吲哚美辛，但不幸的是由于溶解度低而表现不佳。尽管如此，母体支架证明了其作为双光子成像工具用于RAW264.7巨噬细胞和大鼠海马组织中内源性ONOO的比率检测的有效性。这些结果证明了这种基于ESIPT苯并咪唑的平台在诊疗开发和生物成像应用中的实用性。